{"id":498813,"date":"2021-05-26T08:05:34","date_gmt":"2021-05-26T12:05:34","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-jefferies-virtual-healthcare-conference\/"},"modified":"2021-05-26T08:05:34","modified_gmt":"2021-05-26T12:05:34","slug":"oncternal-therapeutics-to-participate-in-jefferies-virtual-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-jefferies-virtual-healthcare-conference\/","title":{"rendered":"Oncternal Therapeutics to Participate in Jefferies Virtual Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SAN DIEGO, May  26, 2021  (GLOBE NEWSWIRE) &#8212; Oncternal Therapeutics (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will present a corporate overview at the Jefferies Virtual Healthcare Conference on <strong>Thursday, June 3, 2021 at 10:30 am Eastern Time. <\/strong><\/p>\n<p>To register in advance for the corporate presentation, sign up <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wHTqKeYgCQV8QzOiKF9PVi_yPcZarNeJ7Y0RxiHVSAmaNVcwmmaekPGUAxNjGpM76ukXy9OvUfI_oY3_LjXEs7b3utTBY9CS42VoHuRPrkM=\" rel=\"nofollow noopener\" target=\"_blank\">here<\/a>. \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/p>\n<p>\n        <strong>Replay Link: <\/strong><br \/>\n        <br \/>A replay will be accessible on the Events &amp; Presentations page of the Investors section on the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BmF3xzk1Uef5rTvZyvL0ZfyOmYlVvfU8LcXu_aZtiKHgYMAsrhfunbspa1UI9QipMk79Q67biemh2Cri_-6-RnD-JSDdvvJlUgCAlUXi3cLY4rg4UHXHJ-ianwUzWdxP9p-eQPTkgltAit9YEUYMN1_DqRq-YNhcH-vA9FsqPmzKRnocqLSoDaLilfEAa0pJsVxK7UtCfCLE2oPJd53ULA==\" rel=\"nofollow noopener\" target=\"_blank\"><u>https:\/\/investor.oncternal.com\/news-and-events\/events-presentations<\/u><\/a>.<\/p>\n<p>\n        <strong><br \/>\n          <strong>About Oncternal Therapeutics:<\/strong><br \/>\n        <\/strong>\n      <\/p>\n<p>Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer generation or progression. The clinical pipeline includes <strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yiZS3W7bqVaQg-2I5E4CsK-xdWOkq2mVLGHh4xeq2c7FFX2rFstIYz50QQXqWSWLmQJbU431d7KHnOx1ywp3ilEtJKtVtaHJNbcUy7WnS0kjJxdn6VTAnSrPyvSLlkLXY4C5GCcp96t9KauEiqf2PvOwXguZtLv5CZD6Sz7mvJVG_PZBDJu9dHUS7GQui89CG9G7l27EzAWydN_wF-C7Fw8l5zdTARK9ndkunT0G3SNbtgXZKFs3myz6gSNACxAow4J52gi-ZHN6Pmyv5y0In-lRHiKd8EIZSiTTtq4wmaokNH20b-JQBM5mmHZOVu8ndU8Cby8qGVx8ShWy0RSBlvHRIwfHIJV26EYAA2-zUHupHUb8IXfd611jjuwSByDX2IaKy6V0D09GLJaqWCvO8GunSy85TtgLdVFO4tetPRZl3cObK2CWStA7hHicjoZo\" rel=\"nofollow noopener\" target=\"_blank\"><u>cirmtuzumab<\/u><u>,<\/u><\/a><\/strong> an investigational monoclonal antibody designed to inhibit the ROR1 pathway, a type I tyrosine kinase-like orphan receptor, that is being evaluated in a Phase 1\/2 clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) and in investigator-sponsored, Phase 1b clinical trial in combination with paclitaxel for the treatment of women with HER2-negative metastatic or locally advanced, unresectable breast cancer, as well as a Phase 2 clinical trial of cirmtuzumab in combination with venetoclax, a Bcl-2 inhibitor, in patients with relapsed\/refractory CLL. Oncternal is also developing a chimeric antigen receptor T cell (<strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=d3THRDUP_Cdnkb-MROeFixPqTqixfTvdEbLpLtVjOXDV1VuACFeUtWZkBW0ynSq1Ihl2pKp3pt6nY3J8_FP5KqazAyrOxP_-TMqi6xDWo6M=\" rel=\"nofollow noopener\" target=\"_blank\"><u>CAR-T<\/u><\/a><\/strong>) therapy that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors. The clinical pipeline also includes <strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=b-QSpg-5JxZr5gQzdID10--VUlSt5i-rsELOAS9T1MlUDHb27pR-GlpW8B7xD_UqFnAa_H9uZQ1Z9mitSwerGf4ECrIg7JNK7fKA39bjbQ4=\" rel=\"nofollow noopener\" target=\"_blank\">TK216<\/a><\/strong>,<strong>\u00a0<\/strong>an investigational targeted small-molecule inhibitor of the ETS family of oncoproteins, that is being evaluated in a Phase 1\/2 clinical trial for patients with Ewing sarcoma alone and in combination with vincristine chemotherapy. More information is available at <strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BmF3xzk1Uef5rTvZyvL0ZSnkFsJbtiVmJ_zo3ug50-uF2gI3bqwuD8O4rThJIyXi50U3KDvRpewhrTAalLTlQg==\" rel=\"nofollow noopener\" target=\"_blank\"><u>https:\/\/oncternal.com<\/u><\/a><\/strong>.<\/p>\n<p>\n        <strong>Oncternal Contacts:<\/strong>\n      <\/p>\n<p>\n        <strong>Company Contact<\/strong><br \/>\n        <br \/>Richard Vincent <br \/>858-434-1113<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7VTudY7QkXGsIO5qD-9S6WuRbm_WIW5RbLwWauLAJJXCI3G2dMT5Hdvya261ejIn5Yu8KawdiYTJece4ZD_oPkZVHBdnlmoe7CqHTv7GTlY=\" rel=\"nofollow noopener\" target=\"_blank\"><u>rvincent@oncternal.com<\/u><\/a><\/p>\n<p>\n        <strong>Investor Contact<\/strong><br \/>\n        <br \/>Corey Davis, Ph.D. \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0<br \/>LifeSci Advisors \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0<br \/>212-915-2577\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_TkOnqLct5Xo35t5b8bf83nXvzGIbtro_QzmFuSIW-u6hpw0APHSO7QGZ8mEiZlhsVBcCSLutcRkhIqYuPXxGTfMUwFufEeYyffyC4xexU1HXRImX9rZ4vZuTgEsoCH5\" rel=\"nofollow noopener\" target=\"_blank\"><u>cdavis@lifesciadvisors.com<\/u><\/a>\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0MTg5OCM0MTk4NjcyIzUwMDA3NDE2MQ==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/a331be47-9551-40f0-b997-776dc0acd116\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) &#8212; Oncternal Therapeutics (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will present a corporate overview at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 10:30 am Eastern Time. To register in advance for the corporate presentation, sign up here. \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Replay Link: A replay will be accessible on the Events &amp; Presentations page of the Investors section on the Company\u2019s website at https:\/\/investor.oncternal.com\/news-and-events\/events-presentations. About Oncternal Therapeutics: Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-jefferies-virtual-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Oncternal Therapeutics to Participate in Jefferies Virtual Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-498813","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Oncternal Therapeutics to Participate in Jefferies Virtual Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-jefferies-virtual-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oncternal Therapeutics to Participate in Jefferies Virtual Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) &#8212; Oncternal Therapeutics (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will present a corporate overview at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 10:30 am Eastern Time. To register in advance for the corporate presentation, sign up here. \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Replay Link: A replay will be accessible on the Events &amp; Presentations page of the Investors section on the Company\u2019s website at https:\/\/investor.oncternal.com\/news-and-events\/events-presentations. About Oncternal Therapeutics: Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped &hellip; Continue reading &quot;Oncternal Therapeutics to Participate in Jefferies Virtual Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-jefferies-virtual-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-26T12:05:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0MTg5OCM0MTk4NjcyIzUwMDA3NDE2MQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-participate-in-jefferies-virtual-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-participate-in-jefferies-virtual-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Oncternal Therapeutics to Participate in Jefferies Virtual Healthcare Conference\",\"datePublished\":\"2021-05-26T12:05:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-participate-in-jefferies-virtual-healthcare-conference\\\/\"},\"wordCount\":336,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-participate-in-jefferies-virtual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0MTg5OCM0MTk4NjcyIzUwMDA3NDE2MQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-participate-in-jefferies-virtual-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-participate-in-jefferies-virtual-healthcare-conference\\\/\",\"name\":\"Oncternal Therapeutics to Participate in Jefferies Virtual Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-participate-in-jefferies-virtual-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-participate-in-jefferies-virtual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0MTg5OCM0MTk4NjcyIzUwMDA3NDE2MQ==\",\"datePublished\":\"2021-05-26T12:05:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-participate-in-jefferies-virtual-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-participate-in-jefferies-virtual-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-participate-in-jefferies-virtual-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0MTg5OCM0MTk4NjcyIzUwMDA3NDE2MQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0MTg5OCM0MTk4NjcyIzUwMDA3NDE2MQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-participate-in-jefferies-virtual-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oncternal Therapeutics to Participate in Jefferies Virtual Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Oncternal Therapeutics to Participate in Jefferies Virtual Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-jefferies-virtual-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Oncternal Therapeutics to Participate in Jefferies Virtual Healthcare Conference - Market Newsdesk","og_description":"SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) &#8212; Oncternal Therapeutics (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will present a corporate overview at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 10:30 am Eastern Time. To register in advance for the corporate presentation, sign up here. \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Replay Link: A replay will be accessible on the Events &amp; Presentations page of the Investors section on the Company\u2019s website at https:\/\/investor.oncternal.com\/news-and-events\/events-presentations. About Oncternal Therapeutics: Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped &hellip; Continue reading \"Oncternal Therapeutics to Participate in Jefferies Virtual Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-jefferies-virtual-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-05-26T12:05:34+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0MTg5OCM0MTk4NjcyIzUwMDA3NDE2MQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-jefferies-virtual-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-jefferies-virtual-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Oncternal Therapeutics to Participate in Jefferies Virtual Healthcare Conference","datePublished":"2021-05-26T12:05:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-jefferies-virtual-healthcare-conference\/"},"wordCount":336,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-jefferies-virtual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0MTg5OCM0MTk4NjcyIzUwMDA3NDE2MQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-jefferies-virtual-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-jefferies-virtual-healthcare-conference\/","name":"Oncternal Therapeutics to Participate in Jefferies Virtual Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-jefferies-virtual-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-jefferies-virtual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0MTg5OCM0MTk4NjcyIzUwMDA3NDE2MQ==","datePublished":"2021-05-26T12:05:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-jefferies-virtual-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-jefferies-virtual-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-jefferies-virtual-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0MTg5OCM0MTk4NjcyIzUwMDA3NDE2MQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0MTg5OCM0MTk4NjcyIzUwMDA3NDE2MQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-jefferies-virtual-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Oncternal Therapeutics to Participate in Jefferies Virtual Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/498813","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=498813"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/498813\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=498813"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=498813"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=498813"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}